1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Blog | Chemxpert

Blogs

Everything you need to know about Propacetamol DMF

Admin
Drug Master File (DMF)
5 August 2025

Chemxpert helps streamline that journey. With verified DMF data and supplier intelligence, it enables you to make confident sourcing and regulatory decisions—faster.Read More

Anti-Diabetic Drugs in India: Market Trends, Innovations & Future

Admin
Drug Development
29 July 2025

India comes second in the world when it comes to diabetic population. There are over 101 million in India that are diabetic.Read More

Top Biosimilar Companies in India | Reasons for Biosimilar Growth in India and Future

Admin
Biosimilars
22 July 2025

Did you know that over $200 billion worth of biologic drugs are about to lose their patents by 2030.Read More

Global API Export Trends 2025: Who’s Leading the Charge?

Admin
Active Pharmaceutical Ingredient
16 July 2025

API exports in 2025 are no longer just a supply chain metric, they have become an important essence of the global pharmaceutical industry.Read More

Top Pharmaceutical Conferences 2025: Ultimate Guide to Latest Events Q3-Q4

Admin
Drug Development
14 July 2025

The pharmaceutical industry's conference landscape is rapidly changing. AI-powered drug discovery dominating biotech events.Read More

Why Most Biosimilars don’t get Approved?

Admin
Biosimilars
10 July 2025

Explore 2025 biosimilar approval trends, regional bottlenecks, and why most applications fail despite rising global market demand.Read More

Drug Approval Process in the USA: Step-by-Step Guide to FDA Approval

Admin
Drug Development
4 July 2025

The U.S. Food and Drug Administration (FDA) sets the global gold standard for drug regulation.Read More

Drug Approval Process in India: Complete Step-by-Step Guide

Admin
Drug Development
3 July 2025

India isn’t just a pharma market. It’s the engine that powers global access to affordable medicine.Read More

How AI Is Transforming Pharma in 2025 with Data-Driven Power

Admin
Pharma Industry
1 July 2025

AI is transforming the pharmaceutical industry in 2025—driving breakthroughs in drug discovery, optimizing manufacturing, and fixing broken supply chains.Read More

Recent Mergers and Acquisitions in the Pharma Sector – 2025 Roundup

Admin
Pharma Industry
30 June 2025

2025 is turning out to be one of the most pivotal years for pharmaceutical M&A activity in recent history.Read More